Cardiac Effects of Norepinephrine After the Initial Phase of Septic Shock

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Previous studies of our team reported the improvement of myocardial contractility both on hemodynamic parameters (by transpulmonary thermodilution) and morphological (by transthoracic echocardiography: TTE), during the early phase of septic shock (during the first 4 hours management of septic shock). However, one can wonder about the effect of NAD on myocardial cardiac ouput and contractility beyond the early phase of septic shock, more precisely beyond the first 24 hours. Indeed, while it continues to act on the stressed blood volume and the diastolic left ventricular perfusion by increasing the diastolic arterial pressure (DAP), it has been reported in old studies that beyond the early phase, the sensitivity of the β1-adrenergic receptors is altered due to the phenomenon of internalization of these receptors, leading to a reduction of the myocardial response to catecholamines. The investigators can then wonder whether norepinephrine still exerts a positive effect on myocardial contractility via the increase in DAP, despite an alteration of the β1-adrenergic pathway. To answer this question, the investigators proposed to evaluate the effects of norepinephrine by TTE on cardiac contractility after the initial phase.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adult patients \>18 years old

• Septic shock after 24 hours from its diagnosis

• MAP\<65 mmHg for which the physician in charge decided to increase NE

Locations
Other Locations
France
Chu Reims
RECRUITING
Reims
Contact Information
Primary
Olfa Hamzaoui
ohamzaoui@chu-reims.fr
3 10 73 69 73
Time Frame
Start Date: 2023-04-21
Estimated Completion Date: 2025-12-21
Participants
Target number of participants: 49
Treatments
Patients with septic shock for 24 hours or more
Adult patients suffering from septic shock, after 24 hours of their diagnosis. Presenting with Mean arterial pressure (MAP)\<65 mmHg or the target MAP For whom the physician in charge decided to increase the norepinephrine dose
Related Therapeutic Areas
Sponsors
Leads: CHU de Reims

This content was sourced from clinicaltrials.gov